Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024591 (
malignant hyperthermia
)
2,353
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 40 year old man, who was suspected on clinical evidence (fever, severe muscle pains,
dark urine
following general anesthesia 8 years ago) of being susceptible to
malignant hyperthermia
, was scheduled for traumatologic surgery. Dantrolene-Sodium 4 mg/kg orally was given prophylactically the day before surgery; as a premedication the patient received morphine and triflupromazine intramuscularly. Anesthesia was induced with flunitrazepam and fentanyl, pancuronium bromide was administered for endotracheal intubation and neuromuscular blockade during surgery. No complications were seen during anaesthesia and the following immediate postoperative period. 10 hrs after surgery an episode of pyrexia lasting about 20 h and an elevation of blood creatine phosphokinase (CPK) has been noted. The remainder of the postoperative course was uneventful. The patient was discharged 9 days later.
...
PMID:[Atypical course of malignant hyperthermia]. 399 99
A 33-year-old man with chronic alcoholism presented with left flank pain and a low-grade fever. He had a previous history of left renal calculi treated by extracorporeal shockwave lithotripsy 3 months previously at a local hospital. Since a stone was impacted at the ureteropelvic junction resulting in septic hydronephrosis, a D-J catheter was introduced to relieve the condition. He underwent fluid therapy with antibiotics. Elective pyelolithotomy was scheduled on day 10. However, persistent pyonephrosis necessitated the removal of the infected kidney. Hyperthermia over 40 degrees C continued after surgery and
dark urine
developed on postoperative day 2. Rhabdomyolysis was suspected because of myoglobulinemia with a high creatine phosphokinase level. Systemic cooling and treatment with fluid and diuretics saved his renal function. He survived episodic
malignant hyperthermia
and was discharged from intensive care unit on postoperative day 5.
...
PMID:[Rhabdomyolysis following nephrectomy for pyonephrosis: a case report]. 1033 Nov 80
Rhabdomyolysis, a term used to describe the rapid breakdown of striated muscle, is characterized by rupture and necrosis of muscle fibers. This process results in the release of cell breakdown products into the bloodstream and extracellular space. Although direct muscle injury remains the most common cause of muscle injury, additional causes include hereditary enzyme disorders, drugs, toxins, endocrinopathies,
malignant hyperthermia
, neuroleptic malignant syndrome, heatstroke, hypothermia, electrolyte alterations, diabetic ketoacidosis and non-ketotic hyperosmolar coma, severe hypo- or hyperthyroidism and bacterial or viral infections. The classic triad of symptoms includes muscle pain, weakness and
dark urine
, although more than 50% of the patients do not complain of muscle pain or weakness. Additional systemic symptoms include fever, general malaise, tachycardia, nausea and vomiting. The laboratory diagnosis is based essentially on the measurement of creatine kinase in serum or plasma. Plasma and urine myoglobin measurement might be useful in the early stages of the syndrome and for identifying a subset of patients with minor skeletal muscle injury. Patient monitoring is pivotal (the mortality rate is as high as 8%), and should be focused on preventing the detrimental consequences, that often include renal disease and coagulopathy. In the pre-hospital setting, forced hydration with 1.5-2 L of sterile saline solution should be started immediately, followed by 1.5-2 L/h. Following hospital admission, continuous hydration should be ensured, alternating the saline solution with a 5% glucose solution. In the presence of myoglobinuria, urine should be alkalinized by use of sodium bicarbonate solution. Clin Chem Lab Med 2010;48:749-56.
...
PMID:Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. 2044 60